Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention & Therapy, Tianjin, China.
J Comp Eff Res. 2023 May;12(5):e230006. doi: 10.57264/cer-2023-0006. Epub 2023 Apr 17.
To compare the effectiveness of PD-1 inhibitor or bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer (nsNSCLC). We retrospectively collected data for patients with advanced nsNSCLC who underwent first-line treatment with PD-1 inhibitor or bevacizumab plus chemotherapy (IC and BC groups). Propensity score matching (PSM) was adopted to balance covariates. 278 patients were enrolled, after PSM (n = 104/group), the objective response rate was 45.1% and 24.0% in the IC and BC groups (p = 0.001). Median progression-free survival (PFS) was 13.5 and 8.2 months (p = 0.007), and duration of response was 14.8 versus 8.1 months (p = 0.007), respectively. In subgroup analysis, the PFS for those patients with PD-L1≥1% (16.2 vs 6.8 months, p = 0.000) was significantly longer in the IC group than that in BC group, but not in the PD-L1<1% subgroup (8.9 vs12.7 months, p = 0.719). PD-1 inhibitor plus chemotherapy was superior to bevacizumab plus chemotherapy as first-line treatment for advanced nsNSCLC, which is debatable for patients with PD-L1<1%.
比较 PD-1 抑制剂或贝伐珠单抗联合化疗治疗晚期非鳞状非小细胞肺癌（nsNSCLC）的疗效。我们回顾性收集了接受 PD-1 抑制剂或贝伐珠单抗联合化疗（IC 组和 BC 组）一线治疗的晚期 nsNSCLC 患者的数据。采用倾向评分匹配（PSM）平衡协变量。共纳入 278 例患者，PSM 后（n=104/组），IC 组和 BC 组的客观缓解率分别为 45.1%和 24.0%（p=0.001）。中位无进展生存期（PFS）分别为 13.5 和 8.2 个月（p=0.007），中位缓解持续时间分别为 14.8 和 8.1 个月（p=0.007）。亚组分析显示，PD-L1≥1%的患者（16.2 vs 6.8 个月，p=0.000）中，IC 组的 PFS 明显长于 BC 组，但 PD-L1<1%的亚组中（8.9 vs 12.7 个月，p=0.719）无差异。PD-1 抑制剂联合化疗作为晚期 nsNSCLC 的一线治疗优于贝伐珠单抗联合化疗，但对于 PD-L1<1%的患者存在争议。
